Dr. Corinne Epperly


Dr. Corinne Epperly has served as a member of our Board of Directors since December 2023. She brings 20 years of experience as a physician and scientist blending medicine and business with a proven track record in oncology drug development. Most recently Dr. Epperly served as the Chief Operating Officer (COO) of CARGO Therapeutics, a clinical-stage, next-generation CAR-T cell therapy company. Here she played a pivotal role in the company’s formation, overseeing its growth from day-one through significant financing milestones including the successful $200 million Series A funding round. At CARGO, her responsibilities included corporate strategy, business development, finance, corporate operations, and early commercial and pipeline planning. Prior to CARGO, Dr. Epperly was Senior Vice President of Strategy and Operations at Iovance Biotherapeutics and also served as the US COO at VBL Therapeutics. Previously Dr. Epperly spent seven years at Bristol Myers Squibb where she played instrumental leadership roles in driving the launches of OPDIVO® (nivolumab) and YERVOY® (ipilimumab) across multiple tumor indications and led global M&A transactions such as the acquisition of Amylin Pharmaceuticals with diabetes partner AstraZeneca and subsequent sale. Earlier in her career, Dr. Epperly worked at Goldman Sachs where she served as an Equity Analyst in Global Pharmaceutical and Biotechnology Investment Research.

Dr. Epperly also serves on the Board of Sastra Cell Therapy, a private cell therapy company, and previously on the Board of AVEO Oncology prior to its acquisition by LG Chem. She holds a Bachelor’s degree in Biochemistry and Biology from the University of Virginia, a Doctorate of Medicine and a Masters of Public Health from the University of North Carolina at Chapel Hill.